In July 2015, the self-examination and verification of drug clinical trial data was officially launched. In July 2015, the CFDA issued the "Announcement on the Implementation of the Self-inspection and Verification of Drug Clinical Trial Data", requiring the 1,622 declared production or import pending review listed in the announcement The self-inspection and verification of drug clinical trial data is carried out in the drug registration application, which marks the official launch of the self-inspection and verification of drug clinical data. Subsequently, CFDA issued 29 announcements successively to guide and notify the development of self-examination and verification of clinical trial data. Drug clinical trial data self-inspection verification process: first self-inspection, then clinical trial data self-inspection verification is divided into two steps: applicant self-inspection and CFDA verification. ① Self-inspection process: According to the CFDA public list, relevant applicants conduct self-inspection of clinical trial data on the registration applications that have been applied for production or import. After self-inspection, if there is a problem with the authenticity of the data, the registration application shall be withdrawn voluntarily; if no problem is found, it shall apply to CFDA for on-site verification. ②Verification process: According to the varieties applied for on-site verification, the verification team publicizes the on-site verification plan and conducts on-site verification, and then adopts a blind review method to conduct centralized review of the verification results. If the clinical data is found to have authenticity problems, the registration application will not be approved; if no problems are found, it will enter the normal review and approval process. Self-inspection results: more than 60% of applicants voluntarily withdrew registration applications, reducing the pressure of CDE review. At present, CFDA has issued 9 announcements, requiring self-inspection and verification of clinical trial data of 2116 pending drug registrations that have been declared for production or import jobs. As of the end of June 2017, in addition to 258 registration applications that do not require verification, such as application for exemption from clinical trials, 1,316 registration applications were withdrawn voluntarily by the applicant after the self-inspection of drug clinical data, accounting for 62.2%; only 542 varieties need to be on-site Verification. This greatly eases the review pressure of CDE in applying for registration of production or import. Verification results: Approximately one third of the registration applications in the 13-phase on-site verification plan have been reviewed as of August 2017. The CFDA Audit and Inspection Center has released a total of 13-phase drug clinical trial data on-site verification plans, with a total of 382 varieties. Among them, 42 enterprises withdrew their registration applications, CFDA approved 43 imports, approved 18 production, approved 5 clinical applications, 8 disapproved, and 266 had no review conclusions. In other words, 30.3% of drug registration applications that have already reviewed and approved results, and 69.7% of drug registration applications have no review conclusions. As of June this year, 60% of the drug verification work has been completed. As of the end of June 2017, 313 of the 542 varieties to be verified have been verified, accounting for 57.7%. Among the checked drug registration applications, 94 were new drug registration applications, 37 were generic drug registration applications, and 182 were imported drug registration applications. Among them, a total of 38 varieties are suspected of falsifying clinical trial data, and the suspected falsification of clinical trial data for generic drug registration applications is the most serious. Main problem: Most of the defects in the clinical part, the problems are more concentrated. According to the on-site inspection report of 313 drug registration applications, a total of 5111 defects were found, including 4583 in the clinical part and 528 in the biological analysis part. The defect items were classified, and many problems were found in clinical trial process records, clinical inspections, laboratory tests and other data traceability, protocol violations, experimental drug management processes and records, and safety records and reports, accounting for 61.8%. Risk reminds the sustainability risk of drug clinical trial data self-examination and verification work; implementation is lower than expected;

Potential vaccine varieties are successively listed, and the industry opens up room for development The domestic vaccine sector was not valued by the market before, because most of the varieties were low-priced first-class vaccines and severely homogenized second-class vaccines, with fierce competition and limited corporate profits. At present, the vaccine industry is in the stage of launching potential varieties and increasing the volume. The AC-Hib triple vaccine and EV71 hand-foot-mouth disease vaccine are in a period of rapid growth after the market. Imported 2-valent and 4-valent HPV vaccines have been approved after 10 years of waiting. , The domestic 13-valent pneumonia conjugate vaccine and HPV vaccine are on the eve of the market, and the industry is at an upward turning point. The vaccine industry is highly concentrated, which is a subdivision of the blue ocean in the pharmaceutical sector According to data from the China National Inspection and Quarantine Institute, there are currently about 35 companies that have issued vaccine batches in China, and there are even fewer companies that have major product research and development, and the market is very concentrated. On the other hand, vaccines are used in the country's large healthy population, especially It is young children, so the vaccine industry is more sensitive, and imported products will be subject to certain restrictions. At present, only domestic products are purchased for national first-class vaccines. In 2016, imported vaccine batches accounted for only 2.3% of the total. The competition pattern of domestic enterprises is good. Moreover, from the perspective of product registration, vaccine oligopoly competition, facing a large domestic healthy population, is the real blue ocean in the field of medicine. The vaccine industry is preferentially treated by policies, and less restricted by bidding and medical insurance The bidding system of the vaccine industry is different from that of medicines. Because of its limited variety, new products can be dynamically added after they are launched, and they are not limited by the bidding schedule, and the volume is fast. Moreover, the second-class vaccine does not occupy medical insurance funds, and the people choose to vaccinate independently. Therefore, the vaccine has always been of high quality and good price, and will not be restricted by medical insurance control fees. In addition, prevention is more economical than treatment. The CDC report in the United States points out that 1 US dollar of vaccine expenditure saves about 5-27 US dollars in treatment costs. Therefore, vaccines are strongly supported by the state and preferential policies. Class II vaccines have consumer product attributes and also benefit from consumption upgrades The second-class vaccine people choose to vaccinate independently, which is a medical product with consumer attributes. China is at the most significant stage of consumption upgrading. Vaccines, as the most effective means to prevent diseases, will have a high degree of acceptance. At present, in China's large consumer goods industry, "upgrade" is a very important investment idea in the market. In the field of medical consumption, it is mainly reflected in the upgrade of rigid medication and the rise of non-rigid high-end medical demand. Vaccines fall into this category. With the popularization of emerging media, people’s perceptions will change more rapidly. In addition, with the increase in payment levels, the vaccination rate is expected to increase.   Investment Advice Vaccines depend on new varieties. The growth of old products is limited. Only when new products are launched will the company's performance increase. Therefore, we focus on vaccine companies with potential varieties: Watson Bio (13-valent pneumonia conjugate vaccine and 2-valent HPV vaccine) To be launched), Kangtai Biology (MRC-5 rabies vaccine is to be launched, and there are many potential varieties under development), Zhifei Biology (AC-Hib vaccine is heavy, and Merck’s 4-valent HPV will be launched soon).   risk warning The risk of product development failure; product promotion not up to expectations; the impact of vaccine industry events.

[China Pharmaceutical Network Industry News] In recent years, Shenzhen has attached great importance to the cultivation and development of biological and life health industries. In the process of industrial transformation, Pingshan District has seized the opportunity, and the biomedical industry has become one of the pillar industries of Pingshan. In addition, at present, the Shenzhen Biomedical Innovation Industrial Park has also introduced two common service platforms for the biological industry-Guangdong Medical Device Quality Supervision and Inspection Institute and the China-Israel Science and Technology Innovation Service Center to promote the healthy development of the biomedical industry. (Shenzhen continues to explore opportunities and paths for the international development of biomedicine) On September 22, the "Shenzhen·Pingshan International Biomedical Industry Innovation and Development Summit" co-sponsored by the Shenzhen Municipal Commission for the Promotion of International Trade and the Pingshan District Government was held in Pingshan District, Shenzhen. Seven academicians from home and abroad, as well as well-known experts and scholars, will visit the scene to discuss the development opportunities and paths of Shenzhen's biomedicine investment under the background of the Guangdong-Hong Kong-Macao Bay Area. In recent years, Shenzhen has attached great importance to the cultivation and development of biological and life health industries. In the process of industrial transformation, Pingshan District has seized the opportunity. The biomedical industry has become one of Pingshan’s pillar industries, and hundreds of billions will be formed during the "13th Five-Year Plan" period. Level of output value scale. The arrival of the Shenzhen Pingshan International Biomedical Industry Innovation and Development Summit will play an important role as a platform for Pingshan and even Shenzhen to integrate high-end resources in the entire industry chain of the biological field and promote domestic and foreign biotechnology exchanges and cooperation. Cross-border integration of biomedical engineering Realize the international development of the industry The construction of the Guangdong-Hong Kong-Macao Greater Bay Area puts forward higher requirements for industrial development. It is not only necessary to enhance the ability to allocate resources and the leading function of the industrial chain, but also to further enhance the ability to radiate the economy to the outside. The Shenzhen Pingshan International Biomedical Industry Innovation and Development Summit was held to gather the cutting-edge wisdom of experts and scholars in the global biomedicine field and elites from all walks of life to discuss in-depth innovative ideas in the development strategy of the Guangdong-Hong Kong-Macao Greater Bay Area and accelerate the crossover of biomedical engineering Integration and advanced layout will realize the large-scale, agglomeration and international development of the biomedical industry. Including American Academy of Engineering, School of Medicine, Academician of the Third World Academy of Sciences, Foreign Academician of Chinese Academy of Engineering Cato T. Laurencin, Ding Jian, Academician of Chinese Academy of Engineering, Yan Deyue, Academician of Chinese Academy of Sciences, Zhang Xuemin, Academician of Chinese Academy of Sciences, Sun Yongkui, Academician of American Academy of Engineering , Zhao Xiaobin, academician of the Royal Society of Chemistry, Han Zhongchao, academician of the French National Academy of Technology, a total of 7 academicians and a group of famous experts and scholars will discuss the development of the biomedical industry. In addition, there are 8 teams participating in the summit roadshow, which will bring the latest research results in biomedicine such as the development of next-generation peptide antibiotics, the precise detection technology of tumors based on exosomes, the research and development and industrialization of articular cartilage regeneration. Prior to this, the Shenzhen Municipal Government has successfully hosted the 6th Biological Exhibition and the 4th "Shenzhen International BT Leaders Summit". Every year, the exhibition attracts hundreds of well-known domestic and foreign companies, research institutions, and experts and scholars from all over the world. Biological resources have played an important role in promoting exchanges and cooperation in biotechnology. "Thirteenth Five-Year" period biological industry base will reach 100 billion output value scale In recent years, Shenzhen has attached great importance to the cultivation and development of biological and life health industries. In the process of industrial transformation, Pingshan District has seized the opportunity, and the biomedical industry has become one of Pingshan’s pillar industries. The Shenzhen National Bio-industry Base in Pingshan District is one of the first batch of 3 bio-industry bases in the country approved by the National Development and Reform Commission in 2005, covering an area of ​​3.29 square kilometers. Over the years, the base has insisted on taking independent innovation as the leading strategy for industrial development, and has introduced more than 70 talent teams at all levels, including academician teams, "Thousand Talents Program" teams, etc., to focus on cultivating technologically-leading market entities. The national bio-industry base adopts the "triple jump" model of incubation, acceleration, and land supply, forming a whole industry chain support system from business incubation to project research and development, from achievement transformation to market expansion, and from financial support to listing and financing. As the iconic supporting facility of Shenzhen's national bio-industry base, Shenzhen Biomedical Innovation Industrial Park is a large-scale industrial carrier constructed to gather high-quality resources in the biomedical field and promote the rapid expansion of high-growth small and medium-sized enterprises. It is also the current city of Shenzhen. The few specialized bio-industrial parks that meet GMP construction standards were constructed by Shenzhen Investment Holdings Co., Ltd. with an investment of 700 million yuan, covering an area of ​​123,400 square meters, with a total construction area of ​​220,000 square meters, and a total of 10 buildings. At present, the Shenzhen Biomedical Innovation Industrial Park has introduced two common service platforms for the biological industry-Guangdong Medical Device Quality Supervision and Inspection Institute and the China-Israel Science and Technology Innovation Service Center. The Guangdong Medical Device Quality Supervision and Inspection Institute is a public participation management institution directly under the Guangdong Food and Drug Administration. It is the only national medical device quality inspection institute designated by the State Food and Drug Administration in South China. It is expected to be completed in the first quarter of 2018. Construction. The China-Israel Science and Technology Innovation Service Center, operated by Israel’s outstanding technology service organizations, will be built as a demonstration platform for the introduction of Israeli high-end industrial projects, technology transfer and technological achievement transformation in the Pearl River Delta region and even the whole country. It will introduce outstanding Israeli industry service companies, Technological service and achievement transformation companies and professional incubator operators promote the achievement transformation of high-quality biomedical projects in Pingshan. Currently, Pingshan’s biomedicine industry has gathered more than 120 biomedicine and medical device companies and service organizations. Among them, there are more than 50 biopharmaceutical companies, including Microchip Biotechnology, which is engaged in the research and development of a class of innovative drugs, Sanofi, a Fortune 500 company, and Heshuntang, which is engaged in the research and development of fine Chinese medicine. There are more than 40 medical device companies, including Libang Precision Instrument Co., Ltd., which is engaged in the research and development of multi-parameter monitoring and in vitro diagnostic equipment, and a new industry biological company, which specializes in the research and development of clinical inspection and analysis instruments, and so on. During the "13th Five-Year Plan" period, the bio-industry base will introduce a number of major projects with a total investment of over 15 billion yuan, forming an eastern bio-industry cluster with an output value of 100 billion yuan. link 7 academicians attended the meeting American Academy of Engineering, School of Medicine, Academician of the Third World Academy of Sciences, Foreign Academician of Chinese Academy of Engineering Cato T. Laurencin World-renowned biomaterial science and engineering expert, orthopedic surgeon, and founder of regeneration engineering. Its engineering and scientific achievements have been outstanding, and have won the President Clinton Award (1995), the Obama Presidential Award (2010), and the Millennium Foundation "Science and Technology Leadership Award" (2001). He created the first artificial ligament and was selected as "Scientific American" "Global Technology Leaders 50" (2007). Ding Jian, Academician of Chinese Academy of Engineering is currently the dean of the School of Pharmacy, University of Chinese Academy of Sciences, and the director of the Academic Committee of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Its focus is on the discovery of new targeted anti-tumor molecules, the discovery of new mechanisms of action, and the confirmation of new biomarkers, which are the systematic research goals, and important progress has been made in the research of molecularly targeted anti-tumor drugs. Yan Deyue, Academician of the Chinese Academy of Sciences Macromolecular chemist, long-term research on the kinetic theory of non-steady state polymerization, polymer conformation statistics, molecular design of hyperbranched polymers and supramolecular self-assembly of irregular polymers, and discovered macro-scale supramolecules in the laboratory Self-assembly phenomenon. Academician of the Chinese Academy of Sciences Zhang Xuemin He has successively served as chief scientist of major national scientific research projects, academic leader of the "Tumor Biology" innovative research group of the National Foundation of China, member of the Special Committee of the Food Safety Committee of the State Council, and has long been engaged in research on the relationship between inflammation and tumors. The main research results have been successively in Published in international academic journals such as NatureImmunology and NatureMedicine. He has won the "National Natural Science Award", "Tan Jiazhen Life Science Achievement Award" and so on. Sun Yongkui, Academician of the American Academy of Engineering Ph.D. in Chemistry from California Institute of Technology. He has won the 2005 British Association of Chemical Engineers AstraZeneca Green Chemistry and Engineering Excellence Award, and the 2005 and 2006 US Presidential Green Chemistry Challenge Awards (US Environmental Protection Agency, Washington). Academician of the Royal Society of Chemistry Zhao Xiaobin Currently a member of the Royal Society of Chemistry, a chartered chemist, a member of the Society of Materials, Minerals and Mining, a member of the British Institute of Materials, a member of the American Society for Biomaterials, has published 45 scientific papers and works, and holds a number of international patents. Its main research direction is the surface body repair technology of biological materials with biocompatibility. Han Zhongchao, Academician of the French National Academy of Technology is mainly engaged in the research and development of blood vascular cell molecular biology and biotechnology, and has achieved many international leading academic achievements in the research of stem cells, megakaryocytes and platelets, angiogenesis and its control, chemokines, etc. Original title: Exploring opportunities and paths for the international development of biomedicine teaches you the whole process of using APP (Pharmaceutical Link) to seize business opportunities (Source: NetEase)

Last week (9.18~9.22) a total of 135 listed companies in the two cities disclosed their investigations. From the perspective of industry distribution, the surveyed companies are mainly concentrated in the electronics, chemical, medical and biological industries. According to industry classification, the companies surveyed last week were mainly concentrated in the three major industries of electronics, chemicals, and pharmaceuticals and biology, and the number of companies involved were 23, 15 and 13 respectively. Last week (9.18~9.22), a total of 135 listed companies in the two cities disclosed their investigations. From the perspective of industry distribution, the surveyed companies are mainly concentrated in the electronics, chemical, medical and biological industries. According to industry classification, the companies surveyed last week were mainly concentrated in the three major industries of electronics, chemicals, and pharmaceuticals and biology, and the number of companies involved were 23, 15 and 13 respectively. In the electronics industry, among the 23 electronics industries surveyed, 12 companies have disclosed their performance forecasts for the first three quarters. From the perspective of the type of forecast, 5 companies have increased in advance, 2 companies have continued to make profits, 3 companies have increased slightly, 1 company lost the first time, and 1 company has decreased slightly. Among them, Han's Laser expects the net profit range of the first three quarters to be 1.393 billion yuan to 1.582 billion yuan, a year-on-year increase of 120% to 150%, the most impressive performance. Han's Laser announced that the substantial increase in the company's performance was mainly due to the strong demand for consumer electronics, new energy, high-power and PCB equipment, and the company's product orders increased significantly over the same period last year. The 12 companies in the electronics industry surveyed forecast the first three quarters: In the chemical industry, Shanghai Securities analyst Shao Rui pointed out in his industry research report on September 19 that “the chemical industry is not only used in traditional industries, Emerging fields such as new materials are also indispensable. In the past, many high-tech industries were monopolized by foreign-funded enterprises. With the advancement of domestic technology, the gradual transfer of downstream emerging industries to the country and mergers and acquisitions, etc. The field of new materials is developing rapidly. Investors can make arrangements for industries with strong performance certainty. TFT, adhesives, printing consumables, ceramic materials, lithium battery materials, functional films, etc. all have layout value." In terms of individual stocks, Gosuncn has received 49 institutions in total last week, ranking first; Xinhecheng has received 46 institutions, ranking second; Nasda received 37 institution surveys, ranking third. At the research meeting of Gosuncn, the relevant person in charge revealed that the company and Huawei are cooperating in some businesses and have signed a cooperation agreement. Huawei recognizes the company's three-dimensional cloud defense system very much. Currently, the three-dimensional cloud defense system has been used in some parts with Huawei. In cooperation projects. In addition, with regard to the future development plan of the Internet of Vehicles business, the relevant person in charge of Gosuncn pointed out that the Internet of Vehicles is a relatively mature field, a relatively large market, and a clearer profit model in the segmented field of the Internet of Things. Gosuncn will mainly use hardware as the carrier and carry a software platform. The business prospects of this business will be very impressive. In terms of the types of research institutions, securities firms have the strongest research interest, participating in the research of 108 companies; public funds participated in the research of 58 companies, ranking second; Sunshine Private Equity participated in the research of 51 companies, ranking third; overseas institutions and insurance companies were respectively Participated in the survey of 31 and 33 listed companies. From the perspective of specific institutions, private equity Star Stone Investment investigated the clean environment, Heju Investment investigated Xinhecheng, Qianhe Capital investigated China Media Holdings, Supply and Marketing Daji, and Chongyang Investment investigated Goldwind Technology, Wen's Shares, and Xinhecheng. Hecheng, Zhuque Investment researched Jingrui shares and New Times; for public funds, Bosera researched Ninestar, Gosuncn, Guangwei Composites, and Huitianfu researched Anhui Technology, Guangwei Composites, and Harvest Research With Huayi Brothers and Salt Lake, E Fund investigated Wen's shares, Gosuncn and Bank of Hangzhou; in terms of overseas institutions, Abu Dhabi Investment Bureau investigated BOE A and Rongzhilian, and Allianz Investment investigated Helitai and Zhongbai Group. , Deutsche Securities researched Costa and Shinwanda, Morgan Stanley researched Shinwanda, Oupai Home Furnishing, and Hao Laike, the Central Bank of Norway researched GEM and Kenrui Woneng, and Nomura Securities researched Goldwind. , Xinwangda, Credit Suisse investigated Opai Home and Haolaike. (Original title: The agency focused on researching electronics, chemical, pharmaceuticals and biology last week)

[Opinions of Experts from China Pharmaceutical Network] Recently, 7 academicians from home and abroad, through keynote speeches and theme discussions, discussed the development opportunities and paths of biomedicine under the background of the Guangdong-Hong Kong-Macao Greater Bay Area and discussed the development of the biomedical industry. In the future, we will actively provide advice and suggestions for the development of the biomedical industry in Pingshan District. 　 The "regeneration technology" brought by Academician Cato Laurentson has attracted a lot of attention. ★Academician of the National Academy of Engineering-Cato T. Laurencin Academician of the American Academy of Engineering, Medical School, Third World Academy of Sciences, and foreign academician of the Chinese Academy of Engineering. Received a doctorate in medicine from Harvard University in 1987. He is a world-renowned biomaterial science and engineering expert, orthopedic surgeon, and founder of regenerative engineering. "My research is mainly in the field of regenerative cells and stem cells. I hope that living cells can be reprogrammed and used to restore injured tissues to their existing functions. This technology has won the international medical Oscar known as the American medical profession. prize. Whether it is translational medicine or regenerative engineering, it is a new way of thinking that connects basic medical research and clinical treatment. Shenzhen has shown great momentum in this regard. The government is investing heavily in biomedical research and strives to become A leader in the global field, and the various advantages and conditions that Pingshan has, I finally made a choice. " ★Academician of Chinese Academy of Engineering——Ding Jian Tumor pharmacologist, graduated from Kyushu National University in Japan with a doctorate degree in 1992. He was elected as an academician of the Chinese Academy of Engineering in 2009 and is currently the dean of the School of Pharmacy, University of Chinese Academy of Sciences. "To be truly innovative, we must pay attention to basic research. Shenzhen is already at the forefront of the country in this regard. For Pingshan, we can start by building a government-supported public platform to continuously improve various functions, including biological drugs and Basic testing of technology, as well as some large-scale scientific research instruments, allow companies to meet various R&D needs in Pingshan, which is also conducive to attracting companies to settle down and help companies grow." ★Academician of the Chinese Academy of Sciences——Yan Deyue Polymer chemist, professor at Shanghai Jiaotong University, received a PhD in natural science from Catholic University of Leuven, Belgium in 2002, and was elected as an academician of the Chinese Academy of Sciences in 2005. "Chemotherapy is currently the most effective way to treat cancer, but it also has some shortcomings and problems, such as easy induction of drug resistance and strong side effects. For this reason, we proposed the concept of small molecule nanomedicine and conducted animal experiments. Some results have been achieved, and the next step is to strive to move to the clinic as soon as possible, hoping to establish a platform for transformation in Pingshan." ★Academician of the Chinese Academy of Sciences——Zhang Xuemin Received a doctorate degree from the Academy of Military Medical Sciences in 1995. He successively served as the chief scientist of the national major scientific research project and the academic leader of the "Tumor Biology" innovative research group of the National Foundation of China. "Nowadays, there are no particularly effective drugs for some major diseases, and we can only try to solve them through innovation. In this regard, Shenzhen has obvious advantages. As Shenzhen continues to increase mechanism innovation and improve innovation policies, it cannot be done and cannot be done elsewhere. , If you do it slowly, you can speed up the clinical experience when you come to Shenzhen." ★Academician of the National Academy of Engineering——Sun Yongkui In 1983, he went to the California Institute of Technology to study and obtained a Ph.D. in chemistry. He was awarded the AstraZeneca Green Chemistry and Engineering Excellence Award from the British Association of Chemical Engineers and the President's Green Chemistry Challenge Award. In 2016, he was elected as a member of the American Academy of Engineering. “The research and development of new drugs requires a variety of basic scientific support and an excellent research and development ecological environment. I think the research and development environment can be solved by establishing a large platform to shorten the time period, accelerate the development of new drugs, and attract some innovative talents. Let them focus on the development of their own fields." ★Academician of the Royal Society of Chemistry-Zhao Xiaobin Ph.D. in Medical Materials, Institute of Polymer Research, Nankai University, Ph.D., Department of Bioengineering, Biomaterials and Artificial Instruments, University of Strathclyde, UK. He is currently a Fellow of the Royal Society of Chemistry and a Chartered Chemist. "The development of the Pingshan National Biomedical Base can learn from Australia's practices and actively introduce high-quality projects from outside, which can reduce costs and increase the success rate after entering the market, thereby accelerating the growth and development of the base." ★Academician of the French National Academy of Technology-Han Zhongchao Professor of Nankai University School of Medicine, doctoral supervisor, and head of the Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, and was elected as a foreign academician of the French Academy of Medical Sciences in 2006. "Stem cells and immune cells have created a new therapeutic approach or treatment method, and opened up a brand-new therapeutic effect for some diseases that are difficult to cure by medicine. Stem cell regenerative medicine, coupled with immune cells, will be a revolution in medicine. Pingshan should pay attention to the introduction of such scientific research institutions and enterprises with very large clinical application prospects." Original title: The collision of passion and ideas explores the future of the biomedical industry teaches you the whole process of using APP (Pharmaceutical Link) to seize the business opportunity of medicine (Source: Shenzhen Special Zone News)